Ovarian Cancer – Epidemiology Forecast to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Ovarian cancer is the most lethal gynecologic cancer and overall a leading cause of cancer incidence and mortality worldwide. The disease is defined as uncontrolled cell growth in the ovaries, although research has shown that the disease may actually originate in the fallopian tubes.

GlobalData epidemiologists used age- and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, and used the observed survival rates to calculate the five-year diagnosed prevalent cases, taking into account the significant relationship between age and ovarian cancer incidence, survival, and prevalence. GlobalData epidemiologists applied country-specific incidence rates of ovarian cancer, wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of ovarian cancer cases, including both cancer of the ovary and cancer of the fallopian tube. In 2018, the 7MM had 63,331 diagnosed incident cases of ovarian cancer. This is expected to increase to 66,000 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 0.42%. The increase is driven by changes in incidence rates in the 7MM. In 2018, the 7MM had 180,626 five-year diagnosed prevalent cases of ovarian cancer. This is expected to increase to 191,896 diagnosed prevalent cases by 2028, at an AGR of 0.62%. The US had the highest number of diagnosed incident and five-year diagnosed prevalent cases of ovarian cancer. The development of more effective screening tools for an early diagnosis, including a better understanding of the pathogenesis of the different histologic subtypes of ovarian cancer, would improve survival and increase disease prevalence.

Scope

The Ovarian Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of ovarian cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of ovarian cancer; five-year diagnosed prevalent cases of ovarian cancer; diagnosed incident cases of ovarian cancer by cancer stages at diagnosis; diagnosed incident cases of cancer of the ovary by histologic subtype; diagnosed incident cases of ovarian cancer by germline and somatic BRCA1/2 mutations; diagnosed incident cases of ovarian cancer with HRD; and diagnosed incident cases of epithelial ovarian cancer with FRα overexpression.

The ovarian cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

 The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

 The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Ovarian Cancer Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global ovarian cancer market.

Quantify patient populations in the global ovarian cancer market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups that present the best opportunities for ovarian cancer therapeutics in each of the markets covered.

Understand magnitude of ovarian cancer population by mutations and associated biomarkers.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ovarian Cancer: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors

3.3 Global and Historical Trends

3.3.1 7MM Trends in Diagnosed Incidence

3.3.2 7MM Trends in Observed Survival

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for Ovarian Cancer (2018–2028)

3.5.1 Diagnosed Incident Cases of Ovarian Cancer

3.5.2 Age-Specific Diagnosed Incidence of Ovarian Cancer

3.5.3 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer

3.5.4 Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis

3.5.5 Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype

3.5.6 Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation

3.5.7 Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation

3.5.8 Diagnosed Incident Cases of Ovarian Cancer with HRD

3.5.9 Diagnosed Incident Cases of EOC with FRα Overexpression

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

Table

Table 1: Risk Factors for Ovarian Cancer

Figures

Figure 1: 7MM, Diagnosed Incident Cases of Ovarian Cancer, Women, Ages ≥18 Years, 2018 and 2028, N

Figure 2: Diagnosed Incidence of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2008–2028, Cases per 100,000 Population

Figure 3: Sources Used and Not Used for Diagnosed Incident Cases of Ovarian Cancer

Figure 4: Sources Used for Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis

Figure 5: Sources Used for Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype

Figure 6: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation

Figure 7: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation

Figure 8: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with HRD

Figure 9: Sources Used for EOC Cases with FRα Overexpression

Figure 10: Diagnosed Incident Cases of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2018

Figure 11: Age-Specific Diagnosed Incident Cases of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2018

Figure 12: Five-Year Diagnosed Prevalent Cases of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 13: Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 14: Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 15: Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 16: Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 17: Diagnosed Incident Cases of Ovarian Cancer with HRD, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 18: Diagnosed Incident Cases of EOC with FRα Overexpression, 7MM, Women, Ages ≥18 Years, 2018, N

Frequently asked questions

Ovarian Cancer – Epidemiology Forecast to 2028 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Ovarian Cancer – Epidemiology Forecast to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ovarian Cancer – Epidemiology Forecast to 2028 in real time.

  • Access a live Ovarian Cancer – Epidemiology Forecast to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.